Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial.
Mark Opdam, Annelot G J van Rossum, Marlous Hoogstraat, Gergana Bounova, Hugo M Horlings, Erik van Werkhoven, Ingrid A M Mandjes, A Elise van Leeuwen-Stok, Sander Canisius, Harm van Tinteren, Alex L T Imholz, Johanneke E A Portielje, Monique E M M Bos, Sandra Bakker, Jelle Wesseling, Lennart Kester, Jacco van Rheenen, Emiel J Rutgers, Renee X de Menezes, Lodewyk F A Wessels, Marleen Kok, Hendrika M Oosterkamp, Sabine C Linn, MATADOR trialists’ group for the Dutch Breast Cancer Research Group (BOOG)
iScience 27(8) 110425
摘要
摘要
The primary objective of the prospective, randomized, multicenter, phase 3 biomarker Microarray Analysis in breast cancer to Taylor Adjuvant Drugs Or Regimens trial (MATADOR: ISRCTN61893718) is to generate a gene expression profile that can predict benefit from either docetaxel, doxorubicin, and cyclophosphamide (TAC) or dose-dense scheduled doxorubicin and cyclophosphamide (ddAC). Patients with a pT1-3, pN0-3 tumor were randomized 1:1 between ddAC and TAC. The primary endpoint was a gene profile-treatment interaction for recurrence-free survival (RFS). We observed 117 RFS events in 664 patients with a median follow-up of 7 years. Hallmark gene set analyses showed significant association between enrichment in immune-related gene expression and favorable outcome after TAC in hormone receptor-negative, human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC) (triple-negative breast cancer [TNBC]). We validated this association in TNBC patients treated with TAC on H&E slides; stromal tumor-infiltrating lymphocytes (sTILs) ≥20% was associated with longer RFS (hazard ratio 0.18, p = 0.01), while in patients treated with ddAC no difference in RFS was seen (hazard ratio 0.92, p = 0.86, p interaction = 0.02).
KM 提取结果
0 个 Figure · 0 个 KM 面板